Securing a HTA approval in Europe makes sound commercial sense but it’s proving easier said than done. Negative or restrictive HTA recommendations are on the increase, and market access professionals are scratching their heads wondering what can realistically be done to ease the process.
We spoke to experts at seven top tier pharmaceutical companies to find out their latest thinking on European HTAs, the difficulties faced, and how they are being overcome. We used their detailed responses to collate a fresh perspective on the current trends and to identify the key success factors involved in securing a positive HTA recommendation in Europe.
Various issues were identified:
- One size does not fit all: Why is it imperative to have a strategic approach to HTAs in Europe? What should European MA teams know about fundamental market differences?
- Difficulty seeing the bigger picture: There’s no question that Europe has plenty of potential. Use this report to step back and assess key markets where your HTA strategy can be applied.
- Lack of clarity around what’s really needed: Find out how to think like a HTA agency, gain a better understanding of their requirements, and ultimately improve your strike rate.
- Insufficient resources: There are no shortcuts to success, which means that significant resources are needed if HTA approvals are to be achieved. Use this report to build internal understanding of the nuances of European agencies and show why more support is vital.